High-Deductible Health Plans Fall From Grace In Employer-Based Coverage
Once viewed as a promising cost-control tool, such insurance faces new competition on benefits menus from more traditional insurance. But, according to new research, none of those choices is getting less expensive.
Putting Oversized Health Care Costs Upfront — On T-Shirts
The Maryland Health Care Commission has created a consumer education campaign that puts the costs of common health care procedures on a place where people might see them – T-shirts.
The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
States Looking To Tax Opioids Pin Hopes On November Elections
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
As An Investor In Biotech Stock, Republican Chris Collins May Have Overshared
Rep. Chris Collins talked one time too many, according to federal prosecutors who on Wednesday charged him with violating insider trading laws.
Drug Trade Group Quietly Spends ‘Dark Money’ To Sway Policy And Voters
Grants by top pharma group to lightly regulated, politically active nonprofits dwarf its conventional campaign spending.
Déjà Voodoo: Pharma’s Promises To Curb Drug Prices Have Been Heard Before
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
Administration Eases Way For Small Businesses To Buy Insurance In Bulk
The Trump administration issued the final rule on association health plans, which supporters say will make coverage more affordable for some employees but led others to warn about “junk insurance.”
Why Did Novartis Pay Trump’s Lawyer $1.2 Million? Look At Its Drug Prices
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
As Proton Centers Struggle, A Sign Of A Health Care Bubble?
Companies pushed proton machines and counted on advertising, doctors and insurers to ensure a steady business treating cancer. But the dollars haven’t flowed in as expected.
How A Drug Company Under Pressure For High Prices Ratchets Up Political Activity
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
Paying Hospitals To Keep People Out Of Hospitals? It Works In Maryland.
The state’s ambitious payment overhaul has begun to demonstrate savings and a change in culture, say new reports.
As States Target High Drug Prices, Pharma Targets State Lawmakers
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
Drug Industry Spent Millions To Squelch Talk About High Drug Prices
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
Churning, Confusion And Disruption — The Dark Side Of Marketplace Coverage
The Affordable Care Act has increased the number of people with insurance, but shopping around for plans puts a burden on patients, especially this year.
Hospitals Find Asthma Hot Spots More Profitable To Neglect Than Fix
Months of reporting and rich hospital data portray life in the worst asthma hot spot in one of the worst asthma cities: Baltimore. The medical system knows how to help. But there’s no money in it.
Obamacare: comprar seguro es más complicado que nunca. Aquí, algunas tretas
Es esencial que conozca sus opciones en base a los ingresos y al tamaño de su familia. Aquí, algunas respuestas clave para entender el mercado de seguros.
Obamacare Shopping Is Trickier Than Ever. Here’s A Cheat Sheet.
This year, more than ever, it is important to know your options.
Do Pharma’s Claims On Drug Prices Pass The Smell Test? We Found 5 Stinkers.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don’t We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
